Cullinan Therapeutics Email Format
Biotechnology ResearchMassachusetts, United States51-200 Employees
Cullinan Therapeutics is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases and cancer. The company emphasizes modality-agnostic, targeted therapies, including T cell engagers, with the aim of delivering first- or best-in-class, high-impact treatments. It is headquartered at 1 Main Street in Cambridge, Massachusetts, and maintains a workforce of 51 to 200 employees; its website is https://cullinantherapeutics.com. Recent disclosures indicate ongoing development of CLN-978 for systemic lupus erythematosus and rheumatoid arthritis, and licensing activity related to velinotamig. Reported revenue in the provided data is in the range of $50 million to $100 million.
1-888-653-2347 
support@leadiq.com 
